TFAM and colorectal cancer: Silencing TFAM expression in colorectal cancer mediates metabolic reprogramming, inducing α-ketoglutarate (α-KG)-mediated inhibition of the Wnt/β-catenin signaling pathway, thus suppressing tumor initiation [94].